PLENARY KEYNOTE SESSIONS

THURSDAY, AUGUST 8, 2024 | 11:20 am – 1:20 pm

11:20 am Organizer’s Remarks
Nikki Cerniuk, Conference Producer, Cambridge Innovation Institute

11:25 am Accelerating Cell and Gene Therapy: Current Challenges and Future Directions
Bruce L. Levine, PhD, Barbara & Edward Netter Professor Cancer Gene Therapy, Center for Cellular Immunotherapies, University of Pennsylvania
New designs for genetically modified T cells include switches and potency enhancements that will be required for targeting solid tumors. Determining the critical quality attributes, dose, potency, and anticipating pharmacokinetics of a living, dividing drug presents unique challenges. Improving patient access depends not only on scientific progress in targeting, gene modification, and cellular manipulation, but also on meeting automation, engineering, clinical site onboarding, and health policy challenges.

11:55 Transition to Lunch

12:05 pm LUNCHEON PRESENTATION: HCAb Harbour Mice Advances Multispecific, CAR T, and ADC Therapy in a New Level
Jiyong Zhang, Vice President Head of Business Development, Business Development, Nona Biosciences
HCAb Harbour Mice of Nona Biosciences is the first fully human Heavy Chain only Antibody (HCAb) transgenic mice platform in history. It is optimized, clinically validated with global patent protection. Fully human heavy chain only Antibodies have high affinity and have excellent biophysical characteristics. They are the ideal antibody format to generate a multitude of next-generation therapeutic modalities, including bispecific/multispecific antibodies, ADCs, CAR-based, and mRNA therapeutics.

12:35 pm PLENARY KEYNOTE PANEL: Presentation to be Announced